Welcome to our dedicated page for Crescita Therape news (Ticker: CRRTF), a resource for investors and traders seeking the latest updates and insights on Crescita Therape stock.
Crescita Therapeutics Inc. (OTC US: CRRTF; TSX: CTX) is a Canadian commercial dermatology company that regularly issues detailed news releases about its operations, financial performance and strategic agreements. As a company with in-house R&D and manufacturing capabilities and three defined segments—Commercial Skincare, Licensing and Royalties, and Manufacturing and Services—its news flow covers a range of topics relevant to investors and industry observers.
Readers of this news page can expect recurring coverage of quarterly and annual financial results, where Crescita reports revenue by segment, gross profit, operating expenses, net income or loss, and non-IFRS measures such as EBITDA and Adjusted EBITDA. These releases often explain how performance in the Skincare, Licensing and Manufacturing segments contributed to overall results and describe factors such as contract manufacturing volumes, licensing payments related to Pliaglis®, and sales of branded skincare products.
Crescita’s news also highlights licensing and distribution developments for Pliaglis, including commercialization and development license agreements, exclusive distribution agreements in specific territories, and changes such as the mutual termination of a licensing agreement with Croma Pharma GmbH and the resulting reversion of rights to Crescita. Updates on regulatory pathways for Pliaglis in markets such as China, through partners responsible for clinical trials and approvals, appear in these communications.
Another recurring theme is contract manufacturing and strategic asset acquisitions. The company has announced an amended contract manufacturer supply agreement with a global skincare client, an exclusive manufacturing and supply agreement with a Canadian healthcare services provider for sanitary products, and acquisitions of assets from Occy Laboratoire Inc. and Laboratoire Provence-Canada Inc. News items describe how these arrangements affect manufacturing volumes, plant utilization and the product and client base.
Additional releases cover corporate actions and governance, such as approvals and activity under normal course issuer bids, results of annual general and special meetings of shareholders, and participation in investor conferences. For ongoing insight into Crescita’s financial performance, partnerships and manufacturing activities, this page aggregates the company’s official news in one place.
Crescita Therapeutics Inc. (CRRTF) held its 2021 Annual General and Special Meeting in Laval, Québec, where shareholders voted on key matters. All nominated directors were elected with significant support: Daniel N. Chicoine (86.9%), David A. Copeland (96.5%), Anthony E. Dobranowski (94.8%), John C. London (96.5%), and Thomas Schlader (94.7%). Ernst & Young was reappointed as external auditors with 89.1% approval. Furthermore, Crescita's Share Incentive Plan was approved with 84.7% support. The company remains focused on delivering innovative dermatology solutions.
Crescita Therapeutics reported Q1-F2021 results with revenue at $3,265, down from $3,815 in Q1-F2020, marking a $550 decline. Gross profit also fell to $2,116 from $2,464, a decrease of $348. Operating expenses dropped to $2,413 from $2,825, resulting in an adjusted EBITDA of $87 compared to $112, a $25 decrease. However, cash reserves improved significantly from $9,334 to $13,944. The company launched NCTF for skin revitalization in April, and received a U.S. patent for CTX-102 with protection until 2040, which could aid future projects.
Crescita Therapeutics Inc. (OTC US: CRRTF) announces that its President and CEO, Serge Verreault, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 9:30 AM EST. He will discuss important business highlights and the company’s growth strategy. The conference, focusing on the Canadian healthcare sector, allows investors to interact with major companies. One-on-one meetings with Crescita’s management team will also be available during the event. For registration, click HERE.